Maravai LifeSciences Reports 8.5% Revenue Growth in Q2 2026, Net Loss Reduced by 69%

Maravai LifeSciences Holdings, Inc. reported a revenue increase of 8.5% for the second quarter of 2026, reaching $51.4 million compared to $47.4 million in the same period of 2025. For the first half of 2026, revenue rose 24.4% to $117.3 million, up from $94.2 million year-over-year. The growth was primarily driven by the TriLink segment, which saw a 11.5% increase in revenue to $34.7 million for the second quarter and a 37.3% increase to $82.1 million for the first half, largely due to heightened demand for research materials and GMP products. The Cygnus segment also contributed, with a modest revenue increase of 2.8% for the quarter and 2.1% for the half-year.

The company's gross profit for the second quarter surged to $20.7 million, a 165.8% increase from $7.8 million in the prior year, while gross profit for the first half reached $54.4 million, up 250.8% from $15.5 million. This improvement in profitability was attributed to a significant reduction in cost of revenue, which fell by 22.3% in the second quarter and 20.1% in the first half, reflecting the benefits of the 2025 Corporate Realignment Plan. Operating expenses also decreased substantially, with total operating expenses for the second quarter dropping 51.7% to $35.7 million, and for the first half down 45.3% to $71.6 million.

Maravai's net loss for the second quarter was $21.6 million, a 69.0% reduction from a loss of $69.8 million in the same quarter of 2025. The loss attributable to Maravai LifeSciences Holdings, Inc. was $12.4 million, compared to $39.6 million in the prior year. For the first half, the net loss was $28.0 million, down from $122.7 million. The company reported an Adjusted EBITDA of $8.7 million for the second quarter, a significant turnaround from a negative $10.4 million in the same period last year, and $29.0 million for the first half, compared to a loss of $21.0 million in 2025.

In terms of strategic developments, Maravai completed a refinancing of its debt on June 2, 2026, entering into a new credit agreement that includes a $150 million term loan and a $30 million revolving credit facility. This refinancing allowed the company to repay all outstanding amounts under its previous credit agreement, enhancing its liquidity position. As of June 30, 2026, Maravai had cash and cash equivalents of $70.1 million, down from $216.9 million at the end of 2025, primarily due to significant debt repayments.

Looking ahead, Maravai anticipates continued focus on its core business segments while exploring opportunities for geographic expansion and product innovation. However, the company noted that it does not expect further high-volume orders for its CleanCap products related to COVID-19 vaccine programs for the remainder of 2026, which may impact future revenue streams. The company remains committed to managing its operational costs and enhancing its product offerings to meet evolving market demands.